Myasthenia Gravis - Global ﾂ鮓ｹﾔｭｴｴ Outlook (2017-2026)

Publication ID:

SMRC1218041

Publication Date:

December 1, 2018

Pages:

185

Publisher:

Stratistics MRC

Countries:

Global [1]

USD 4,150.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ is accounted for $1,215.00 million in 2017 and is expected to reach $3,651.25 million by 2026 growing at a CAGR of 13.0% during the forecast period. Increasing health care spending & improving health care infrastructure, increase in occurrence of autoimmune disorders and strong pipeline in its treatment are some of the key factors propelling the market growth. However, limited availability of FDA approved drugs and costly treatment options are some issues restricting the market growth.

Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Moreover, it is characterized by fatigue and weakness of skeletal muscles. Therefore, it occurs in all races, males & females, and at any age. On the other hand MG is not thought to be directly hereditary nor is it transmittable. It does occasionally occur in more than one member of the same family.

Amongst treatment, drug treatment segment commanded considerable market share in the global market owing to the factors responsible for modifying the immune response of the immune system by inhibition of white blood cell activity. Based on geography, Asia Pacific region is expected to register highest market growth rate during the forecast period. Due to Several non-governmental and governmental organizations in the region are concerned in organizing awareness programs

Some of the key players in Myasthenia Gravis market include Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceuticals International, Inc., Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies) and Shire plc

Treatments Covered:
窶｢ Rapid Immunotherapies
窶｢ Drug Treatment

Regions Covered:
窶｢ North America
o US
o Canada
o Mexico
窶｢ Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
窶｢ Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
窶｢ South America
o Argentina
o Brazil
o Chile
o Rest of South America
窶｢ Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- ﾂ鮓ｹﾔｭｴｴ share assessments for the regional and country level segments
- ﾂ鮓ｹﾔｭｴｴ share analysis of the top industry players
- Strategic recommendations for the new entrants
- ﾂ鮓ｹﾔｭｴｴ forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- ﾂ鮓ｹﾔｭｴｴ Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Table Of Contents:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 ﾂ鮓ｹﾔｭｴｴ Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging ﾂ鮓ｹﾔｭｴｴs
3.7 Futuristic ﾂ鮓ｹﾔｭｴｴ Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ, By Treatment
5.1 Introduction
5.2 Rapid Immunotherapies
5.2.1 Thymectomy
5.2.2 Intravenous Immunoglobulin (IVlg)
5.2.3 Plasmapheresis
5.3 Drug Treatment
5.3.1 Chronic Immunomodulators
5.3.2 Monoclonal Antibodies
5.3.3 Cholinesterase Inhibitors

6 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ, By Geography
6.1 Introduction
6.2 North America
6.2.1 US
6.2.2 Canada
6.2.3 Mexico
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 Italy
6.3.4 France
6.3.5 Spain
6.3.6 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 India
6.4.4 Australia
6.4.5 New Zealand
6.4.6 South Korea
6.4.7 Rest of Asia Pacific
6.5 South America
6.5.1 Argentina
6.5.2 Brazil
6.5.3 Chile
6.5.4 Rest of South America
6.6 Middle East & Africa
6.6.1 Saudi Arabia
6.6.2 UAE
6.6.3 Qatar
6.6.4 South Africa
6.6.5 Rest of Middle East & Africa

7 Key Developments
7.1 Agreements, Partnerships, Collaborations and Joint Ventures
7.2 Acquisitions & Mergers
7.3 New Product Launch
7.4 Expansions
7.5 Other Key Strategies

8 Company Profiling
8.1 Novartis AG
8.2 Takeda Pharmaceutical Company Limited
8.3 Grifols, S.A.
8.4 Valeant Pharmaceuticals International, Inc.
8.5 Alexion Pharmaceutical Inc.
8.6 F. Hoffmann-La Roche AG
8.7 CSL Behring
8.8 Baxter International, Inc.
8.9 Avadel Pharmaceuticals, PLC. (Flamel Technologies)
8.10 Shire plc

List of Tables
Table 1 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Treatment (2016-2026) (US $MN)
Table 3 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 4 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Thymectomy (2016-2026) (US $MN)
Table 5 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 6 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 7 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 8 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 9 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 10 Global Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 11 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 12 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Treatment (2016-2026) (US $MN)
Table 13 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 14 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Thymectomy (2016-2026) (US $MN)
Table 15 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 16 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 17 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 18 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 19 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 20 North America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 21 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 22 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Treatment (2016-2026) (US $MN)
Table 23 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 24 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Thymectomy (2016-2026) (US $MN)
Table 25 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 26 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 27 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 28 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 29 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 30 Europe Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 31 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 32 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Treatment (2016-2026) (US $MN)
Table 33 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 34 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Thymectomy (2016-2026) (US $MN)
Table 35 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 36 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 37 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 38 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 39 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 40 Asia Pacific Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 41 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 42 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Treatment (2016-2026) (US $MN)
Table 43 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 44 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Thymectomy (2016-2026) (US $MN)
Table 45 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 46 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 47 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 48 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 49 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 50 South America Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 51 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Country (2016-2026) (US $MN)
Table 52 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Treatment (2016-2026) (US $MN)
Table 53 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 54 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Thymectomy (2016-2026) (US $MN)
Table 55 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 56 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 57 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 58 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 59 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 60 Middle East & Africa Myasthenia Gravis ﾂ鮓ｹﾔｭｴｴ Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)

Companies Mentioned:

Novartis AG
Takeda Pharmaceutical Company Limited
Grifols, S.A.
Valeant Pharmaceuticals International, Inc.
Alexion Pharmaceutical Inc.
F. Hoffmann-La Roche AG
CSL Behring
Baxter International, Inc.
Avadel Pharmaceuticals, PLC. (Flamel Technologies)
Shire plc

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

ﾌ�

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.